Across TCGA pan-cancer cohorts, RUNDC1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RUNDC1 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RUNDC1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RUNDC1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

LUAD, UCEC, and LSCC are the cancer types where RUNDC1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.851	0.947	.001	14	view →
UCEC	DFS	Tertile	II,III,IV	0.916	0.488	.043	4	view →
LSCC	DFS	Tertile	All	0.794	0.538	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: RUNDC1 tumor-vs-normal RNA expression · all RUNDC1 data types